
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis is projected to have a positive outlook based on their promising pipeline, positive phase III data in psoriasis, and an ongoing global clinical trial for TYK2 inhibition in systemic lupus erythematosus. Furthermore, the company's positive data could potentially lead to expansion of their pipeline into other indications beyond psoriasis and SLE, increasing their addressable market and potential for revenue growth. Their current cash position also provides financial stability for operations and future expansions.
Bears say
Alumis is a biopharmaceutical company with a promising pipeline focused on developing TYK2 inhibitors for autoimmune and neurodegenerative diseases. However, the company faces significant competition from other therapies, potential challenges in commercialization, and risks associated with clinical trials and regulatory approval. Additionally, the need for continued funding may result in share dilution for shareholders.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares